Kestra Medical Technologies (NASDAQ:KMTS) Shares Down 4.3% Following Weak Earnings

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) shares traded down 4.3% during mid-day trading on Monday after the company announced weaker than expected quarterly earnings. The company traded as low as $23.13 and last traded at $23.24. 58,981 shares changed hands during trading, a decline of 78% from the average session volume of 269,650 shares. The stock had previously closed at $24.28.

The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter in the previous year, the business posted ($1.18) EPS.

Analysts Set New Price Targets

KMTS has been the topic of several research reports. Wolfe Research initiated coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an “outperform” rating and a $29.00 price objective on the stock. Piper Sandler began coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set an “overweight” rating and a $27.00 price target on the stock. Wells Fargo & Company initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued an “overweight” rating and a $28.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a “buy” rating and a $28.00 target price on the stock. Finally, Bank of America assumed coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a “buy” rating and a $30.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.67.

Kestra Medical Technologies Stock Performance

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.